(InSilico Medicine, Inc.) Insilico applied its AI-powered algorithms to design new preclinical agents with desired properties, including novel inhibitors of JAK, BRAF and EGFR kinases. Insilico Medicine announced the experimental validation of the GAN-RL systems for de novo molecular design.
from EurekAlert! - Social and Behavioral Science https://ift.tt/2usYvj9
No comments:
Post a Comment